If this was a Biotech company on a major market, this would be trading in the dollars, not cents... any one treatment could catapult their share price, even though some of these companies lose hundreds of millions of dollars each year. And let's consider the drug. This drug is for sickle cell which out of the whole continent of Africa, Nigeria has the largest load of cases of sickle cell disorder. The amount of revenue that this can generate is unfathomable, especially when you consider where/when it is marketed in the near future and the fact that this country is in a war right now with this disease. We will be seeing a lot of interest from investors who don't usually touch "penny" stocks... I don't think we'll be at the penny range much longer. The above is just my opinion.
